Gut macrophage phenotype is dependent on the tumor microenvironment in colorectal cancer

Clinical and Translational Immunology

Volumn 5, Issue 4, 2016, Pages

  Norton, Samuel E ^a   Dunn, Elliott T J ^a   McCall, John L ^a   Munro, Fran ^a   Kemp, Roslyn A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD33 ANTIGEN; CD64 ANTIGEN; INTERLEUKIN 6;

AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL HETEROGENEITY; CELL PLASTICITY; CELL POPULATION; CELL SUBPOPULATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; INTESTINE CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 85020628429     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2016.21     Document Type: Article

References (38)

1. GLOBOCAN. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer and World Health Organization, 2012.
2. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654–2666.
3. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
4. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 2012; 65: 159–163.
5. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254–265.
6. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007; 5: 62.
7. Edin S, Wikberg ML, Rutegard J, Oldenborg PA, Palmqvist R. Phenotypic skewing of macrophages in vitro by secreted factors from colorectal cancer cells. PLoS ONE 2013; 8: e74982.
8. Ong SM, Tan YC, Beretta O, Jiang D, Yeap WH, Tai JJ et al. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur J Immunol 2012; 42: 89–100.
9. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007; 13: 1472–1479.
10. Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol 2010; 102: 242–248.
11. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14–20.
12. Williams TM, Wise AF, Alikhan MA, Layton DS, Ricardo SD. Establishing the flow cytometric assessment of myeloid cells in kidney ischemia/reperfusion injury. Cytometry A 2014; 85: 256–267.
13. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002; 16: 391–402.
14. De Calisto J, Villablanca EJ, Mora JR. FcgammaRI (CD64): an identity card for intestinal macrophages. Eur J Immunol 2012; 42: 3136–3140.
15. Zhou H, Liao J, Aloor J, Nie H, Wilson BC, Fessler MB et al. CD11b/CD18 (Mac-1) is a novel surface receptor for extracellular double-stranded RNA to mediate cellular inflammatory responses. J Immunol 2013; 190: 115–125.
16. Smith PD, Smythies LE, Shen R, Greenwell-Wild T, Gliozzi M, Wahl SM. Intestinal macrophages and response to microbial encroachment. Mucosal Immunol 2011; 4: 31–42.
17. Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 2005; 35: 243–251.
18. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142: 481–489.
19. Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka O. CD163 and its role in inflammation. Folia Histochem Cytobiol 2011; 49: 365–374.
20. Rogler G, Hausmann M, Vogl D, Aschenbrenner E, Andus T, Falk W et al. Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol 1998; 112: 205–215.
21. Mia S, Warnecke A, Zhang XM, Malmstrom V, Harris RA. An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a dominant immunosuppressive phenotype. Scand J Immunol 2014; 79: 305–314.
22. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011; 12: 231–238.
23. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539–545.
24. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014; 15: 423–430.
25. Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS ONE 2014; 9: e94188.
26. Girardin A, McCall J, Black MA, Edwards F, Phillips V, Taylor ES et al. Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. Int J Cancer 2013; 132: 1842–1850.
27. Dunn ETJ, Taylor ES, Stebbings S, Schultz M, Butt AG, Kemp RA. Distinct immune signatures in the colon of Crohn's disease and ankylosing spondylitis patients in the absence of inflammation. Immunol Cell Biol (e-pub ahead of print 9 December 2015; doi:10.1038/icb.2015.112).
28. Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 2013; 6: 498–510.
29. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron 2011; 4: 141–154.
30. Wilson HM, Chettibi S, Jobin C, Walbaum D, Rees AJ, Kluth DC. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo. Am J Pathol 2005; 167: 27–37.
31. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350–1356.
32. Setaffy L, Langner C. Microsatellite instability in colorectal cancer: clinicopathological significance. Pol J Pathol 2015; 66: 203–218.
33. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011; 140: 957–965.
34. Mann ER, Bernardo D, English NR, Landy J, Al-Hassi HO, Peake ST et al. Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum. Gut 2016; 65: 256–270.
35. Yang S, Wang B, Guan C, Wu B, Cai C, Wang M et al. Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 2011; 89: 85–91.
36. Wang F, Yang L, Gao Q, Huang L, Wang L, Wang J et al. CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion. Cancer Immunol Immunother 2015; 64: 965–976.
37. Komura T, Sakai Y, Harada K, Kawaguchi K, Takabatake H, Kitagawa H et al. Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Cancer Sci 2015; 106: 672–686.
38. Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 2006; 69: 1037–1042.